SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001618835-23-000018
Filing Date
2023-03-21
Accepted
2023-03-20 21:55:55
Documents
14
Period of Report
2023-03-17
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K evfm-20230317.htm   iXBRL 8-K 34772
2 EX-99.1 a20230320_evfmxdownsizing.htm EX-99.1 9976
6 image_0a.jpg GRAPHIC 27228
  Complete submission text file 0001618835-23-000018.txt   213933

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT evfm-20230317.xsd EX-101.SCH 1896
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT evfm-20230317_lab.xml EX-101.LAB 23892
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT evfm-20230317_pre.xml EX-101.PRE 12519
8 EXTRACTED XBRL INSTANCE DOCUMENT evfm-20230317_htm.xml XML 4126
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

IRS No.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36754 | Film No.: 23747745
SIC: 2834 Pharmaceutical Preparations